Alchemab Therapeutics key facts
as of Oct 2026- Developer of natural protective antibodies designed to keep people free of hard-to-treat diseases in a transformative approach.
- Alchemab Therapeutics is valued at approximately $138.0M as of Oct 2026, set at its later-stage round, Sep 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $32.1M across 1 recorded rounds; the latest was Later Stage VC (Series A) ($31.9M) in Sep 2025.
- Notable investors include Innovate UK, RA Capital Management, DCVC, SV Health Investors, Camford Capital — 11 tracked in total.
- Status: Privately Held (backing).
Valued at $138.0M at its later-stage round, Sep 2025. Nothing has traded since.
- ·The complete investor list: 11 names
- ·Watch Alchemab Therapeutics: the Monday email on marks, rounds and moves
Alchemab Therapeutics funding rounds
1 roundsWho backs Alchemab Therapeutics
11+Membership and data by Private Market View
Alchemab Therapeutics valuation
Alchemab Therapeutics was valued at $138 million at its later-stage round in Sep 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Alchemab Therapeutics raised?
Alchemab Therapeutics has raised $32.1 million across 1 recorded round since 2025. The largest was a $31.9 million Series A in Sep 2025.
Alchemab Therapeutics investors
11 investors are on record for Alchemab Therapeutics, including Innovate UK, RA Capital Management, DCVC and SV Health Investors. By type, the record holds 6 venture capital firms and 1 asset manager. The Series A in Sep 2025 drew 6 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Sparrow Pharmaceuticals ($139 million), Imbria Pharmaceuticals ($132 million) and Tahoe ($131 million).
About Alchemab Therapeutics
Developer of natural protective antibodies designed to keep people free of hard-to-treat diseases in a transformative approach. The company's antibodies are found through an unbiased and function-first approach using three complementary processes and technologies, enabling patients to control the power of naturally protective antibodies and get themselves treated.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 60
- Website
- alchemab.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.